- Company
- Yuhan has secured 260 billion won in technology fee in 3 yrs
- by Chon, Seung-Hyun Nov 22, 2021 05:52am
- Yuhan Corporation is creating a case of securing additional technology fees by advancing to the development stage even after exporting new drug technologies. It has secured a total of 260 billion won in new drug technology exports over the past 3 years. It has secured more money with additional technology fees than the down payment secured by ex
- Company
- Viatris Korea will participate in the IMPACT WEEK
- by Eo, Yun-Ho Nov 22, 2021 05:52am
- Vitris Korea celebrated its first anniversary. On the 16th, Viatris announced that it will participate in the IMPACT WEEK designated by the world to mark the first anniversary of its launch, reflect on the past year, and carry out activities to commemorate the first anniversary with executives and employees. During Impact Week, Viartris wi
- Policy
- AML drug that returned after 7 years is approved in Korea
- by Lee, Tak-Sun Nov 19, 2021 05:52am
- An acute leukemia treatment that withdrew its new drug application (NDA) and then was reapproved by the FDA in 2017 has now been approved in Korea. The drug is Pfizer’s ‘Mylotarg (gemtuzumab ozogamicin).’ On the 18th, the Ministry of Food and Drug Safety approved Prizer’s 'Mylotarg inj.4.5mg.’ The drug is indicated for the treatment
- Policy
- The CSO reporting system will be reviewed
- by Lee, Jeong-Hwan Nov 19, 2021 05:52am
- A bill that mandates government reporting of drug sales and promotional agencies (CSOs) and a bill that regulates illegal hospital subsidies between hospitals, pharmacies, and agents in exchange for prescriptions will be reviewed by the National Assembly's subcommittee on the 24th.The government has also published a bill to designate late ni
- Policy
- Is Celltrion developing a combination of HBP?
- by Lee, Tak-Sun Nov 19, 2021 05:51am
- Attention is focusing on whether Celltrion, which has secured domestic copyrights for ARB-based hypertension treatment Edarbi (Azilsartan Medoxomil), will develop a combination that combines Edarbi and Amlodipine. Attention is focusing on whether Celltrion will also stand out in the hypertension treatment market, which is the domain of tra
- Policy
- Competition intensifies in Forsteo market with 4 latecomers
- by Lee, Tak-Sun Nov 19, 2021 05:51am
- Products with the same ingredient as the world’s first bone anabolic agent 'Forsteo(Teriparatide),' which was finally able to receive reimbursement in Korea 10 years after its approval, are rapidly entering the market. Domestic pharmaceutical companies are occupying the follow-on market with their Forsteo latecomers. Already 4 teriparatid
- Policy
- A law, proposed to prohibit overuse of drug price reduction
- by Lee, Jeong-Hwan Nov 19, 2021 05:51am
- The ruling party has proposed an additional bill to regulate the abuse of lawsuits by some pharmaceutical companies, including an injunction to suspend execution of the government's drug price cut. Following Rep. Kim Woni of the Democratic Party of Korea, Rep. Nam In-soon also proposed a partial amendment to the National Health Insurance
- Company
- All-round prostate cancer treatment Xtandi with solid growth
- by Nov 18, 2021 05:55am
- Xtandi (enzalutamide)' rose to the ranks and became a blockbuster drug last year after continuously extending its indication in prostate cancer, a field that lacked treatment options. Although the drug was approved later than its competitor, through its continuous expansion effort, Xtandi became the only single-agent drug that is approved fo
- Company
- Domestic approval of Tabrecta is imminent
- by Eo, Yun-Ho Nov 18, 2021 05:54am
- According to related industries, the MFDS is conducting a final review for marketing approval of Tabrecta (Capmatinib) of Novartis Korea. Approval is possible within this year. MET mutations account for about 3% to 4% of metastatic non-small cell lung cancer, and as there have been no treatments, interest in these new drugs is increasing.
- Policy
- MFDS reviews emergency use of Merck’s oral COVID-19 pill
- by Lee, Tak-Sun Nov 18, 2021 05:54am
- The Ministry of Food and Drug Safety announced that it has started review for the Emergency Use Authorization of US Merck’s oral COVID-19 treatment, ‘Lagebvrio (molnupiravir).’ Also, the ministry added that a preliminary review is also in progress for US Pfizer’s ‘Paxlovid.’ On the 17th, the Korea Disease Control and Prevention Agen
